Memorial Hospital Research Laboratories

The Charles Rudin Lab

Share
Back to top

Research

Charles M. Rudin, MD, PhD
Charles M. Rudin, MD, PhD

Physician-scientist Charles M. Rudin, Chief of the Thoracic Oncology Service, leads research that focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models including patient-derived xenografts. These studies are integrated with early phase clinical trials.

The Charles Rudin Lab Members

Featured News

Scientists Learn More about How Lung Cancer Becomes Resistant to Drugs
By switching from one cellular identity to another, lung cancer cells can evade targeted therapies. MSK scientists are trying to stop that from happening.
Charles Rudin and Dana Pe'er
Molecular Atlas of Small Cell Lung Cancer Reveals Unusual Cell Type That Could Explain Why It’s So Aggressive
Stem-like cells that make up only a tiny fraction of the total cells in a lung tumor could be the key to stopping the disease’s deadly spread, say researchers at Memorial Sloan Kettering.
MSK Scientists Reveal Biology of Shape-Shifting Lung Cancer
Lung cancer has an uncanny ability to change its identity to resist drugs. Researchers are learning what drives these changes.

View All Featured News

Publications Highlights

Quintanal-Villalonga A, Durani V, Sabet A, Redin E, Kawasaki K, Shafer M, Karthaus WR, Zaidi S, et al. Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers. Sci Transl Med. (2023)

Rudin CM, Balli D, Lai WV, Richards AL, Nguyen E, Egger JV, Choudhury NJ, Sen T, Chow A, Poirier JT, Geese WJ, Hellmann MD, Forslund A. Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation. J Thorac Oncol. (2023)

Jaspers JE, Khan JF, Godfrey WD, Lopez AV, Ciampricotti M, Rudin CM, Brentjens RJ. IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models. J Clin Invest. (2023).

Chow A, Uddin FZ, Liu M, Dobrin A, Nabet BY, Mangarin L, Lavin Y, Rizvi H, Tischfield SE, Quintanal-Villalonga A, Chan JM, et al. The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer. Immunity. (2023) 

Chemi F, Pearce SP, Clipson A, Hill SM, Conway AM, Richardson SA, Kamieniecka K, Caeser R, et al. cfDNA methylome profiling for detection and subtyping of small cell lung cancers. Nat Cancer. (2022) 

View All Publications

People

Charles M. Rudin, MD, PhD

Charles M. Rudin, MD, PhD

  • Physician-scientist Charles Rudin focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models.
  • MD, PhD, University of Chicago Pritzker School of Medicine
[email protected]
Email Address
View physician profile
Physician profile

Members

Fathema Uddin
Fathema Uddin

Graduate Student

Emily Costa

Graduate Student

Álvaro Quintanal Villalonga
Álvaro Quintanal Villalonga

Co-Director, The Charles Rudin Lab

Kelly Clarke
Kelly Clarke

Senior Program Manager

Barbara Mello, PhD
Barbara De Mello

Senior Research Assistant

Vidushi Durani
Vidushi Durani

Graduate Student

Kenta Kawasaki
Kenta Kawasaki

Research Fellow

Dennis Kinyua
Dennis Kinyua

Research Technician

Yonit Lavin

Postdoctoral Fellow

Jake June-Koo Lee

Postdoctoral Fellow

Parvathy Manoj
Parvathy Manoj

Lab Manager

Evelyn Nguyen

Graduate Student

Esther Redin Resano
Esther Redin Resano

Research Fellow

Amin Sabet

Graduate Student

Sohrab Salehi

Postdoctoral Fellow

Harsha Sridhar
Harsha Sridhar

Senior Research Technician

Salomon Tendler
Salomon Tendler

Research Fellow

Hong Zhong

Research Assistant

Lab Alumni
Viola Allaj
Viola Allaj

Research Associate, Pfizer Inc.

Metamia Ciampricotti
Metamia Ciampricotti

Technical Application Liaison, Mission Bio

John Poirier
John T. Poirier

Assistant Professor, Director, Preclinical Therapeutics Program, Perlmutter Cancer Center, NYU Langone Health

Joseph Chan
Joseph Chan

Assistant Member

Eric Gardner
Eric Gardner

Postdoctoral Research Fellow, Harold Varmus Lab, WCMC

Christopher Hulton, BS, MS
Christopher Hulton

Senior Scientist, Drug Discovery Biology, Treeline Biosciences, Cambridge, MA

Corrin Wohlhieter
Corrin Wohlhieter

Senior Associate, Clarion Life Sciences

James Laird
James Laird

Medical Resident, Yale School of Medicine

Pictured: Benjamin Lok
Benjamin Lok

Clinician-Scientist, Princess Margaret Cancer Centre and Assistant Professor of Radiation Oncology, University of Toronto

Nisarg Shah
Nisarg Shah

Lab Manager, University of Pennsylvania

Andrew Chow
Andrew Chow

Clinical Director in Oncology Early Development, Merck

W. Victoria Lai
Victoria Lai

Senior Global Development, Late Oncology Lung, Astra Zeneca

Hirokazu Taniguchi
Hirokazu Taniguchi

Assistant professor, Nagasaki University Hospital, Department of Respiratory Medicine

Rebecca Caeser
Rebecca Caeser

Senior Scientist, National Cancer Center, Singapore

Arielle Elkrief

Assistant Professor, McGill University

Jaspers Janneke
Janneke Jaspers

Technology Transfer Officer, Starfish Innovations

Michael Liu
Michael Liu

Research Technician

Linde Miles
Linde Miles

Assistant Professor, University of Cincinnati

Kathryn M. Tully
Kathryn M. Tully

Scientist 1 at Ratio Therapeutics

Lab Affiliations

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Career Opportunities

Apply now

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Charles M. Rudin discloses the following relationships and financial interests:

  • Amgen
    Professional Services and Activities
  • AstraZeneca
    Professional Services and Activities
  • Bridge Medicines
    Professional Services and Activities
  • D2G Oncology
    Professional Services and Activities
  • Daiichi Sankyo
    Intellectual Property Rights
  • Earli Inc.
    Equity
  • Harpoon Therapeutics, Inc.
    Professional Services and Activities
  • Jazz Pharmaceuticals
    Professional Services and Activities

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures

Related topics: